Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

M Simonelli,E Garralda,F Eskens,M Gil-Martin,C-J Yen,R Obermannova,Y Chao, S Lonardi,B Melichar,V Moreno,M-L Yu,A Bongiovanni,E Calvo,S Rottey,J-P Machiels,A Gonzalez-Martin,L Paz-Ares, C-L Chang,W Mason,C-C Lin,D A Reardon,M Vieito, A Santoro, R Meng,G Abbadessa,F Menas, H Lee,Q Liu, C Combeau,N Ternes, S Ziti-Ljajic,C Massard

ESMO Open（2022）

引用 6|浏览31

暂无评分

摘要

•The combination of Isa + Atezo was well tolerated, showing a manageable safety profile.•Tumor-infiltrating CD38+ immune cells were reduced and almost cleared after treatment.•Isa + Atezo did not significantly modulate Tregs or PD-L1 expression in the TME.•CD38 inhibition does not improve responsiveness to PD-L1 blockade in these patients.

查看译文

关键词

isatuximab,atezolizumab,anti-CD38,anti-PD-L1,solid tumors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要